The disease-modifying therapy fingolimod can slow the rate of brain atrophy in children with MS in the same way as it does in adults, an MRI study has shown. A follow up to the PARADIGMS randomised controlled trial involving 215 people aged 10-18 with paediatric-onset multiple sclerosis (PoMS) has shown that fingolimod significantly reduced the ...
Fingolimod slows brain atrophy in children with MS
By Michael Woodhead
11 Mar 2020